Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIRDIE trial
2023-505839-12-01Phase 3Authorised
- Sponsor
- Franciscus Gasthuis & Vlietland
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in severe asthma comparing Mepolizumab cohort with Dupilumab cohort (2 cohorts). Primary endpoint: Number of injections during follow-up in intervention vs control groups (mepolizumab and dupilumab). Planned start Sep 2023; status: authorised.
02
Drugs
mepolizumabdupilumab
03
Conditions
severe asthma
Beyond the preview
Go deeper on 2023-505839-12-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505839-12-01.